Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 11/20 | 0.55 |
| ▸ | CRBN | Q96SW2 | 11/20 | 0.55 |
| ▸ | IKZF2 | Q9UKS7 | 4/20 | 0.39 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23541304 | 1.00 | DDB1 (0.55) | DDB1CRBNIKZF2IKZF1FABP4 | |
| SCHEMBL22526742 | 1.00 | DDB1 (0.55) | DDB1CRBNIKZF2IKZF1FABP4 | |
| SCHEMBL26206493 | 0.95 | DDB1 (0.53) | DDB1CRBNIKZF2IKZF1FABP4 | |
| SCHEMBL26206490 | 0.95 | DDB1 (0.53) | DDB1CRBNIKZF2IKZF1FABP4 | |
| SCHEMBL23553717 | 0.95 | DDB1 (0.53) | DDB1CRBNIKZF2IKZF1FABP4 | |
| SCHEMBL23540574 | 0.91 | DDB1 (0.56) | DDB1CRBNIKZF2DGAT1 | |
| SCHEMBL26205869 | 0.89 | DDB1 (0.53) | DDB1CRBNIKZF2IKZF1 | |
| SCHEMBL26205867 | 0.89 | DDB1 (0.53) | DDB1CRBNIKZF2IKZF1 | |
| SCHEMBL22526822 | 0.89 | DDB1 (0.51) | DDB1CRBNIKZF2IKZF1 | |
| SCHEMBL22526042 | 0.89 | DDB1 (0.51) | DDB1CRBNIKZF2IKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| WO-2020206424-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | DDB1 3993/4885CRBN 171/4885IKZF2 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.